Publications
197 results found
Krell J, James CR, Shah D, et al., 2011, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome, CLINICAL BREAST CANCER, Vol: 11, Pages: 153-160, ISSN: 1526-8209
- Author Web Link
- Cite
- Citations: 15
Palan M, Shousha S, Krell J, et al., 2011, Breast cancer in the setting of HIV., Pathology Research International, Vol: 2011, ISSN: 2090-8091
Oncogenesis in immunocompromised patients occurs due to a number of factors including reduced immune surveillance or other viral pathogens. Breast cancer, unlike other non-AIDS-defining cancers, does not appear associated and has rarely been reported. We describe a case with evidence of immune reactivity around the tumor, but not in the tumor itself.
Palmieri C, Shah D, Krell J, et al., 2011, Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era, CLINICAL BREAST CANCER, Vol: 11, Pages: 93-102, ISSN: 1526-8209
- Author Web Link
- Cite
- Citations: 12
Krell J, Newsom-Davis T, Bower M, et al., 2011, Coinfection with hepatitis B virus does not increase the risk of HIV-associated non-Hodgkin lymphoma, HIV MEDICINE, Vol: 12, Pages: 37-38, ISSN: 1464-2662
Stebbing J, Adams C, Krell J, et al., 2011, HBV and lymphoma: HIV matters, AIDS, Vol: 25, Pages: 274-275, ISSN: 0269-9370
Krell J, Januszewski A, Yan K, et al., 2011, Role of fulvestrant in the management of postmenopausal breast cancer., Expert Rev Anticancer Ther., Vol: 11, Pages: 1641-1652
Fulvestrant is a form of endocrine therapy used in the treatment of postmenopausal breast cancer. It has a unique mechanism of action in that it causes the degradation of estrogen receptor and therefore has been labeled a selective estrogen receptor downregulator. Unlike the selective estrogen receptor modulator tamoxifen, it has no agonistic properties and is therefore a pure anti-estrogen. Given its low level of bioavailability and presystemic metabolism, it has been formulated as an intramuscular injection. A number of dosing regimens have been utilized - these include a dose of 250 mg monthly ('approved dose'), an initial 500 mg followed by 250 mg on days 14 and 28, and thereafter 250 mg every 28 days ('loading dose'), or 500 mg on days 0, 14 and 28, and thereafter every 28 days ('high dose'). This article will review its unique mode of action and preclinical data, as well as clinical data for different dosing regimens and data for its combination with aromatase inhibitors. Fulvestrant is a well-tolerated drug and its toxicities will also be reviewed. The optimal position of fulvestrant in sequential endocrine therapy has yet to be defined.
Krell J, Ewart EK, Stebbing J, 2010, Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer, EUROPEAN JOURNAL OF CANCER, Vol: 46, Pages: 2867-2869, ISSN: 0959-8049
Palmieri C, Krell J, James CR, et al., 2010, Rechallenging with anthracyclines and taxanes in metastatic breast cancer, NATURE REVIEWS CLINICAL ONCOLOGY, Vol: 7, Pages: 561-574, ISSN: 1759-4774
- Author Web Link
- Cite
- Citations: 52
Kirkdale R, Krell J, Brown CO, et al., 2010, The cost of a QALY, QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, Vol: 103, Pages: 715-720, ISSN: 1460-2725
- Author Web Link
- Cite
- Citations: 25
Zebrowski A, Wilson L, Lim A, et al., 2010, Intramedullary spinal cord metastases in breast cancer are associated with improved longer-term systemic control, FUTURE ONCOLOGY, Vol: 6, Pages: 1517-1519, ISSN: 1479-6694
- Author Web Link
- Cite
- Citations: 10
Shah O, Gojis O, Krell J, et al., 2010, Management and outcome of HER2-positive breast cancer treated with and without adjuvant trastuzumab: The Imperial College London experience, JOURNAL OF CLINICAL ONCOLOGY, Vol: 28, ISSN: 0732-183X
Krell J, James CR, Shah D, et al., 2010, Treatment and outcome of metastatic HER2-positive breast cancer relapsing post adjuvant trastuzumab exposure, JOURNAL OF CLINICAL ONCOLOGY, Vol: 28, ISSN: 0732-183X
Gojis O, Rudraraju B, Alifrangis C, et al., 2010, The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease, EJSO, Vol: 36, Pages: 224-229, ISSN: 0748-7983
- Author Web Link
- Cite
- Citations: 30
Krell J, Harper-Wynne C, Miles D, et al., 2009, What is the evidence for rechallenging with anthracyclines or taxanes in metastatic breast cancer? A review of the data., J Clin Oncol, Vol: 27
1072 Background: Anthracyclines and taxanes are widely used in the adjuvant setting for high risk, early stage breast cancer. This raises the issue of what is the optimal therapy for those patients who relapse, and what the potential role, if any, there is for rechallenge with these agents. The current evidence base for rechallenging with anthracyclines/anthracediones and taxanes in metastatic breast cancer (MBC) is examined in this study. METHODS: Medline/Pubmed database searches were performed upto October 2008 to identify studies in which patients (pts) were rechallenged with anthracyclines/anthracediones or taxanes in MBC. RESULTS: The efficacy data, as well as the safety data relating to neurotoxicity and cardiotoxicity from these studies, are summarized in the Table. Twenty-seven studies were identified (20=anthracycline/anthracedione, 7= taxane) of which only two were prospective studies. Both were small (n= 74 & 51) and related to anthracycline rechallenging. CONCLUSIONS: Evidence exists to support rechallenging with anthracyclines and taxanes. However, there are few prospective data on reexposure to taxanes and no data comparing anthracyclines versus taxanes following adjuvant exposure to both agents, supporting the need for clinical trials in this area. Such trials should ideally incorporate a cross-over design at treatment failure, which would shed light on the optimal sequence in which these agents should be administered. [Table: see text] No significant financial relationships to disclose.
Krell J, Harper-Wynne C, Miles D, et al., 2009, What is the evidence for rechallenging with anthracyclines or taxanes in metastatic breast cancer? A review of the data, 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 20
Bower M, Stebbing J, Tuthill MH, et al., 2008, Recovery of cellular immunity following chemotherapy for AIDS related non Hodgkin's lymphoma, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Bower M, Stebbing J, Tuthill M, et al., 2008, Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma, BLOOD, Vol: 111, Pages: 3986-3990, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 24
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.